Telavancin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bone and Joint Infections

Publication date: Available online 17 September 2017
Source:Diagnostic Microbiology and Infectious Disease
Author(s): Julie Harting, Francisco Fernandez, Rob Kelley, Tim Wiemken, Paula Peyrani, Julio Ramirez
This retrospective, case series describes our experience with the use of telavancin in patients with methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis and prosthetic joint infection. The primary objectives were clinical outcomes and adverse events (AEs), and a secondary outcome described microbiological susceptibility. Fourteen patients were enrolled. Median duration of therapy was fifty-eight days, and four patients had concurrent bacteremia. End-of-treatment outcomes were available in 78% of patients, with a clinical success rate of 91%. 30-day and 12-month outcomes were also obtained. Seven patients experienced AEs. Infusion-related reactions were most common, and three AEs required discontinuation of therapy. All MRSA isolates had a telavancin MIC ≤0.06μg/ml, which is susceptible. This study indicates that telavancin may have a role in treatment of MRSA osteomyelitis and prosthetic joint infection. Our study describes clinical success and adverse events for long duration of therapy, up to eight weeks.



from ! ORL Sfakianakis via paythelady.61 on Inoreader http://ift.tt/2xP8S4U
via IFTTT